Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 80 /hr

★★★★★

☆☆☆☆☆

Hire Dr. James H.

United Kingdom

USD 80 /hr

Medicinal Chemist - Senior Research Scientist at the University of Oxford

Profile Summary

I am an experienced medicinal chemist, trained at the University of Oxford (DPhil) and Stanford University (Postdoc). Currently, I am a senior scientist at the University of Oxford, project leading several drug discovery initiatives and overseeing all phases from ideation to in vivo proof of concept studies. I have broad experience encompassing medicinal and organic chemistry, biochemistry, biophysics, assay development, cell biology, and in vivo biology. I have been responsible for the mentoring and training of a diverse range of PhD and master's students. Should you require assistance with a medicinal chemistry project, I am fully equipped to provide the necessary guidance and support. Websites: www.linkedin.com/in/james-holt-martyn-84b358ba https://scholar.google.com/citations?user=26qF4PEAAAAJ&hl=en https://www.researchgate.net/profile/James-Holt-Martyn https://www.cardioscience.ox.ac.uk/bhf-centre-of-research-excellence/our-team/james-holt-martyn

Subject Matter Expertise

• ★ Medicinal Chemistry
• ★ Drug Design
• ★ Structure-Activity Relationship (SAR) Studies
• ☆ Catalysis
• ☆ Coordination Compounds
• ☆ Natural Product Chemistry
• ☆ Molecular Modeling
• ☆ Molecular Docking
• ☆ Analytical Chemistry
• ☆ Spectroscopy
• ☆ IR Spectroscopy
• ☆ NMR Spectroscopy
• ☆ Mass Spectrometry
• ☆ Organometallic Chemistry
• ☆ Organic Chemistry
• ☆ Retrosynthesis
• ☆ Peptide Synthesis
• ☆ Biochemistry
• ☆ Biochemical Assays
• ☆ Oxidative Stress & Mitochondrial Function
• ☆ Enzyme Activity Assays
• ☆ Binding Assays
• ☆ Molecular Biology
• ☆ Epigenetics
• ☆ Oligonucleotide Synthesis
• ☆ Kinases
• ☆ Cell Biology
• ☆ Cell-Based Assays
• ☆ Cell Signaling Pathways
• ☆ Applied Chemistry
• ☆ Biomarker Discovery
• ☆ Primary Cells
• ☆ High Throughput Screening (HTS)
• ☆ Drug Target Identification
• ☆ Hit-to-Lead & Lead Optimization
• ☆ Phenotypic Assays
• ☆ Combinatorial Chemistry
• ☆ Drug Development
• ☆ Small Molecule Drug Development
• ☆ Preclinical ADME/PK/PD
• ☆ Drug-Drug Interactions
• ☆ Preclinical Research
• ☆ Preclinical Pharmacology
• ☆ In vitro Preclinical Toxciology
• ☆ In vivo Preclinical Toxicology
• ☆ Bioavailability
• ☆ Gastroenterology & Hepatology
• ☆ Pancreatic Cancer
• ☆ Endocrinology
• ☆ Hematology
• ☆ Leukemia & Lymphoma
• ☆ Cancer Research
• ☆ Cancer Biology
• ☆ Metabolism & Metabolic Disease
• ☆ Hypothesis
• ☆ Research Methodology
• ☆ Presentation Design
• ☆ Medical Writing
• ☆ Research Summaries & Abstracts
• ☆ Medical Copywriting
• ☆ Technical & Scientific Writing
• ☆ Manuscript & Journal Article Writing
• ☆ Experimental Protocols
• ☆ Literature Review
• ☆ Systematic Literature Review
• ☆ Scientific Proofreading & Editing
• ☆ Proofreading & Editing
• ☆ Grant Writing

Services

• Writing
• Research
• Consulting
• Data & AI
• Product Development

Writing Medical Writing, Technical Writing

Research Fact Checking, Scientific and Technical Research, Systematic Literature Review, Secondary Data Collection

Consulting Scientific and Technical Consulting

Data & AI Data Visualization, Data Processing

Product Development Reverse Engineering

Work Experience

Senior Research Scientist

University of Oxford

November 2020 - Present

Postdoctoral Researcher

Stanford University

September 2018 - September 2020

Education

DPhil (PhD) in Cardiovascular Medicinal Chemistry

University of Oxford

October 2014 - June 2018

Masters of Science

University of Leeds

September 2011 - June 2012

Medicinal Chemistry

University of Leeds

September 2008 - June 2011

Certifications

• DPhil

  University of Oxford

  https://www.cardioscience.ox.ac.uk/bhf-centre-of-research-excellence/our-team/james-holt-martyn

  June 2018 - Present

Publications

JOURNAL ARTICLE

James Holt-Martyn, Hannah Lawson, Vilma Dembitz, Jozef Durko, Yuka Kabayama, Lydia Wang, Louie Van De Lagemaat, Louis Dubusse, Laura Alunno, Amelie Guitart, et al.(2022). Targeting HIF-Hydroxylases Compromises Disease Initiation and Propagation, and Synergises with Current Therapies to Eliminate Cancer Stem Cells in AML . Blood. 140. (Supplement 1). p. 8731--8732. American Society of Hematology

Md. Sailful Islam, Cyrille C. Thinnes, James P. Holt‐Martyn, Rasheduzzaman Chowdhury, Michael A. McDonough, Christopher Schofield(2022). Inhibition of JMJD6 by 2‐Oxoglutarate Mimics . ChemMedChem. 17. (1). Wiley

WD Figg Jr, Michael McDonough, Rasheduzzaman Chowdhury, Yu Nakashima, Zhihong Zhang, James P. Holt‐Martyn, ALEN KRAJNC, Christopher Schofield(2021). Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat . ChemMedChem. Wiley

James P. Holt‐Martyn, Rasheduzzaman Chowdhury, Anthony Tumber, Tzu‐Lan Yeh, Martine I. Abboud, Kerstin Lippl, Christopher T. Lohans, Gareth W. Langley, William Figg, Michael A. McDonough, et al.(2020). Structure‐Activity Relationship and Crystallographic Studies on 4‐Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors . ChemMedChem. 15. (3). p. 270--273. Wiley

James P. Holt-Martyn, Anthony Tumber, Mohammed Z. Rahman, Kerstin Lippl, WD Figg Jr, Michael McDonough, Rasheduzzaman Chowdhury, Christopher Schofield(2019). Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors . MedChemComm. 10. (4). p. 500--504. Royal Society of Chemistry ({RSC})

James Holt-Martyn, Alastair G. Kerr, Lawrence C. S. Tam, Ashley B. Hale, Milena Cioroch, Gillian Douglas, Sarina Agkatsev, Olivia Hibbitt, Joseph Mason, Carole J. R. Bataille, et al.(2017). A Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein Receptor . Journal of Pharmacology and Experimental Therapeutics. 361. (3). p. 417--428. American Society for Pharmacology {\&} Experimental Therapeutics ({ASPET})

TZU-LAN YEH, Thomas M. Leissing, Martine I. Abboud, Cyrille Thinnes, Onur Atasoylu, James P. Holt-Martyn, Dong Zhang, Anthony Tumber, Kerstin Lippl, Christopher Lohans, et al.(2017). Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials . Chem. Sci. 8. (11). p. 7651--7668. Royal Society of Chemistry ({RSC})

Mun Chiang Chan, James P. Holt-Martyn, Christopher J. Schofield, Peter J. Ratcliffe(2016). Pharmacological targeting of the HIF hydroxylases – A new field in medicine development . Molecular Aspects of Medicine. 47-48. p. 54--75. Elsevier {BV}

James Holt-Martyn, Mun Chiang Chan, Onur Atasoylu, Emma Hodson, Anthony Tumber, Ivanhoe K. H. Leung, Rasheduzzaman Chowdhury, Verónica Gómez-Pérez, Marina Demetriades, Anna M. Rydzik, et al.(2015). Potent and Selective Triazole-Based Inhibitors of the Hypoxia-Inducible Factor Prolyl-Hydroxylases with Activity in the Murine Brain . PLOS ONE. 10. (7). p. e0132004. Public Library of Science ({PLoS})

DISSERTATION THESIS

Holt-Martyn, J. (2018). Novel and selective small molecule inhibitors and activators for the prolyl hydroxylase domain enzyme [PhD thesis]. University of Oxford .